These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16218884)

  • 1. Drug-drug interactions of antifungal agents and implications for patient care.
    Gubbins PO; Amsden JR
    Expert Opin Pharmacother; 2005 Oct; 6(13):2231-43. PubMed ID: 16218884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug interactions in critically-ill patients. An important factor in the use of micafungin?].
    Garnacho-Montero J; Jiménez Parrilla F
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():33-7. PubMed ID: 21420575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs.
    Sakaeda T; Iwaki K; Kakumoto M; Nishikawa M; Niwa T; Jin JS; Nakamura T; Nishiguchi K; Okamura N; Okumura K
    J Pharm Pharmacol; 2005 Jun; 57(6):759-64. PubMed ID: 15969931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital.
    Arikan S; Sancak B; Hascelik G
    Med Mycol; 2005 Mar; 43(2):171-8. PubMed ID: 15832560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Systemic antifungals. Pharmacodynamics and pharmacokinetics].
    Catalán M; Montejo JC
    Rev Iberoam Micol; 2006 Mar; 23(1):39-49. PubMed ID: 16499430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP.
    Lempers VJ; van den Heuvel JJ; Russel FG; Aarnoutse RE; Burger DM; Brüggemann RJ; Koenderink JB
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3372-9. PubMed ID: 27001813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical relevance of mechanisms of antifungal drug resistance in filamentous fungi].
    Mellado E; Cuenca-Estrella M; Rodríguez-Tudela JL
    Enferm Infecc Microbiol Clin; 2002 Dec; 20(10):523-29; quiz 530, 539. PubMed ID: 12433354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
    van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin.
    Colburn DE; Giles FJ; Oladovich D; Smith JA
    Hematology; 2004 Jun; 9(3):217-21. PubMed ID: 15204103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.
    Kulemann V; Bauer M; Graninger W; Joukhadar C
    Pharmacology; 2005 Dec; 75(4):165-78. PubMed ID: 16192747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal agents in children.
    Steinbach WJ
    Pediatr Clin North Am; 2005 Jun; 52(3):895-915, viii. PubMed ID: 15925667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    Clin Pharmacokinet; 2000 Feb; 38(2):111-80. PubMed ID: 10709776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.
    Bellmann R; Smuszkiewicz P
    Infection; 2017 Dec; 45(6):737-779. PubMed ID: 28702763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug-drug interaction of antifungal drugs].
    Niwa T; Shiraga T; Takagi A
    Yakugaku Zasshi; 2005 Oct; 125(10):795-805. PubMed ID: 16205037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450.
    Niwa T; Imagawa Y; Yamazaki H
    Curr Drug Metab; 2014; 15(7):651-79. PubMed ID: 25429674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspofungin in the treatment of invasive fungal infections.
    Keady S; Thacker M
    Intensive Crit Care Nurs; 2006 Feb; 22(1):59-62. PubMed ID: 16006127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.
    Groll AH; Walsh TJ
    Expert Opin Investig Drugs; 2001 Aug; 10(8):1545-58. PubMed ID: 11772269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.
    Lei HL; Li LH; Chen WS; Song WN; He Y; Hu FY; Chen XJ; Cai WP; Tang XP
    Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1099-1102. PubMed ID: 29536323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caspofungin: the first representative of a new antifungal class.
    Letscher-Bru V; Herbrecht R
    J Antimicrob Chemother; 2003 Mar; 51(3):513-21. PubMed ID: 12615851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.